The human costs surrounding cervical cancer are staggering:

• Worldwide, cervical cancer is the 2nd most common cancer in women over the age of 44 and kills 275,000 women a year.
• In the US about 12,900 new cases of cervical cancer will be diagnosed and of those, about 4,100 women will die.
• In the EU, 31,300 women develop and 13,600 die from cervical cancer annually.
• The WHO estimates that by 2030 cervical cancer is expected to kill 500,000 women per year.

So what is the size of the population that can benefit most from the PPS? Here are the latest demographic data for the current PPS patent estate:

The ability to bring this life-saving device to a market of over 621 million women who will reuse the PPS over the course of their lives represents an incredible opportunity to rewrite the history of cervical cancer globally. Applying minimal recommended medical guidelines across the ages 25-64 cohort, it can be conservatively projected that every woman, on average, will have 10 tests over those years. Applying that factor against the target population reveals a substantial market opportunity over an extended period of time.

Even with advent of new technologies, collection of cervical cells for analysis will always be required in screening programs to prevent Cervical Cancer. Of the many factors that decrease utilization of the Pap smear, the PPS addresses inherent weaknesses in screening programs:

• Compliance: traditional method invasive and inconvenient
• Accessibility: largest incidence of cervical cancer is in less developed countries due to lack of resources and transportation
• Affordability:
  • Patients - Lack of insurance, inability to take off from work and cost of other living essentials.
  • Government Programs - Equipment costs, maximizing productivity of clinical and administrative resources.
• Cultural: some women do not get Pap smear due to religious doctrine or cultural/social mores.

Expanding its footprint beyond cervical cancer diagnosis, the PPS as a cervical cell collector is proven effective in detecting other conditions. Diagnosing HPV, chlamydia, and gonorrhea becomes more efficient and certain with the PPS. This benefit only expands the market opportunities for the Personal Pap Smear.

By mitigating barriers to the usage of the Pap smear, the PPS provides superior access to healthcare while ensuring earlier detection of anomalous health conditions. This technology promises to become the standard of healthcare the world over for all women from all cultures and unlocks a vast market for the right partner. Are you that partner? Will you be the one?